Log In
Print this Print this

rFVIIIFc (Elocta, Eloctate)

Also known as: Long-lasting rFACTOR VIII

  Manage Alerts
Collapse Summary General Information
Company Biogen Inc.
DescriptionLong-acting recombinant fusion protein consisting of the Fc domain of human immunoglobulin G1 (IgG1) attached to Factor VIII
Molecular Target Factor VIII
Mechanism of ActionFactor VIII replacement
Therapeutic ModalityBiologic: Fusion protein
Latest Stage of DevelopmentMarketed
Standard IndicationHemophilia
Indication DetailsTreat and prevent bleeding in hemophilia A patients; Treat hemophilia A; Treat severe hemophilia A
Regulatory Designation

U.S. - Orphan Drug (Treat hemophilia A);
U.S. - Undisclosed Review (Treat hemophilia A);
EU - Orphan Drug (Treat hemophilia A);
Switzerland - Orphan Drug (Treat hemophilia A)


Swedish Orphan Biovitrum AB; UCB Group

 Product Details
 Archive Items are loading loading
Get a free BioCentury trial today